SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-250165
Filing Date
2022-09-23
Accepted
2022-09-23 16:18:00
Documents
12
Period of Report
2022-09-23
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d283481d8k.htm   iXBRL 8-K 25628
  Complete submission text file 0001193125-22-250165.txt   142454

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA bbio-20220923.xsd EX-101.SCH 2852
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbio-20220923_lab.xml EX-101.LAB 17237
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbio-20220923_pre.xml EX-101.PRE 10810
6 EXTRACTED XBRL INSTANCE DOCUMENT d283481d8k_htm.xml XML 3199
Mailing Address 421 KIPLING STREET PALO ALTO CA 94301
Business Address 421 KIPLING STREET PALO ALTO CA 94301 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 221262557
SIC: 2834 Pharmaceutical Preparations